A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

Journal of Affective Disorders

Volumn 56, Issue 2-3, 1999, Pages 171-181

  Rudolph, Richard L ^a   Feiger, Alan D ^b  

^a WYETH AYERST RESEARCH   (United States)

^b Feiger Health Research Center   (United States)

Author keywords

Depression; Fluoxetine; Remission; Venlafaxine XR

Indexed keywords

FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HAMILTON SCALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033373199     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00067-1     Document Type: Article

References (14)

1. Beasley C.M. Jr., Holman S.L., Potvin J.H. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann. Clin. Psychiatry. 5:1993;199-207.
2. Clerc G.E., Ruimy P., Verdeau P.J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9:1994;139-143.
3. Cunningham L.A. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann. Clin. Psychiatry. 9:1997;157-164.
4. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 90:1986;131-138.
5. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:1990;289-299.
6. Dierick M., Ravizza L., Realini R., Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog. Neuro-Psychopharmacol. Bio Psychiat. 20:1996;57-71.
7. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
8. Montgomery S.A., Asberg M. A new depression rating scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
9. Olfson M., Marcus S.C., Pincus H.A., et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch. Gen. Psychiatry. 55:1998;310-316.
10. Stahl S.M. Are two antidepressant mechanisms better than one? J. Clin. Psychiatry. 58:1997;339-340.
11. Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;320-345 American Psychiatric Association, Washington, DC.
12. Thase M.E. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J. Clin. Psychiatry. 58:1997;393-398.
13. Tollefson G.D., Holman S.L. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int. Clin. Psychopharmacol. 8:1993;253-259.
14. Troy S.M., DiLea C., Martin P.T., et al. Bioavailability of once-daily extended release (XR) venlafaxine compared with the immediate release formulation in healthy adult volunteers. Curr. Ther. Res. 8:1997;492-503.